Meningioma

1. Disease Overview

Meningioma arises from the meninges—the thin layers of tissue that envelop the brain and spinal cord. Most are benign (Grade I), though some can be atypical (Grade II) or malignant (Grade III). It is the most common primary tumor originating within the skull.

Globally, meningioma accounts for approximately 37% of all primary central nervous system tumors. Many remain silent for years, discovered only incidentally on scans performed for unrelated reasons.

China sees a large and growing patient volume, with tens of thousands of new cases annually. This substantial caseload has endowed our neurosurgical and radiosurgery teams with exceptional depth of experience—particularly in managing complex skull-base and parasagittal tumors where millimeter-level precision determines outcomes. At Fosun Health: "The more meningiomas we treat, the more precisely we protect the brain beneath."

2. Core Strengths: Why Choose Fosun Health?

Every neurosurgical center can remove a convexity meningioma. Here is what makes ours different:

Capability 1: No Scalpel Needed — Definitive Radiosurgery

"I have a small meningioma. It is growing slowly, but my surgeon says operating is unnecessary or too risky for now. Is there a way to stop it without opening my skull?"

The challenge: Many meningiomas are discovered small, in patients who are elderly, medically frail, or simply unwilling to undergo craniotomy for a benign tumor. Watchful waiting creates years of anxiety. Surgery carries risks that may outweigh benefits for a small, slow-growing lesion.

Our answer: CyberKnife M6 stereotactic radiosurgery (SRS) for small-to-medium meningiomas:

• Curative-Intent Treatment: CyberKnife delivers 0.1mm sub-millimeter precision radiation to the meningioma over 1–5 sessions. The tumor receives an ablative dose while the brain beneath it receives virtually none. Tumor control rates exceed 90% at 10 years for Grade I meningiomas—matching or exceeding surgical outcomes for appropriately selected cases.

• Non-Invasive, Outpatient: No incision. No anesthesia. No ICU stay. You walk in and walk out. Normal activities resume immediately.

• Ideal for Incidental or Slow-Growing Tumors: For meningiomas <3 cm, particularly in patients over 60 or with comorbidities, SRS offers definitive treatment without the morbidity of open surgery.

• For Skull-Base and Inoperable Locations: Meningiomas of the cavernous sinus, petroclival region, foramen magnum, or optic sheath are often deemed surgically inaccessible. CyberKnife reaches them without entering the skull.

What this means for you: A diagnosis of meningioma does not automatically mean a date with the operating room. For many patients, a few sessions of precision radiosurgery provide lifelong tumor control—without a single stitch.

Capability 2: The Surgery No-Go Zones — Skull Base & Vulnerable Neurovascular Structures

"My meningioma wraps around my optic nerve, or sits on the cavernous sinus, or presses against the brainstem. Every surgeon I have seen says it is too dangerous to operate. Am I out of options?"

The challenge: Certain meningioma locations are the most feared territories in neurosurgery. The cavernous sinus houses the carotid artery and cranial nerves controlling eye movement. The petroclival region abuts the brainstem. The optic sheath threatens vision. Surgery in these zones carries devastating risks: blindness, stroke, paralysis.

Our answer: CyberKnife M6 precision radiosurgery for high-risk anatomical locations:

• Cavernous Sinus Meningiomas: CyberKnife delivers ablative radiation to the tumor while the carotid artery, oculomotor nerves, and pituitary gland receive a fraction of the dose. Tumor control with preserved eye movement and hormonal function.

• Petroclival & Posterior Fossa: For tumors pressing the brainstem or cerebellum, 0.1mm precision ensures the brainstem surface dose is minimized while the tumor receives a curative dose. No posterior fossa syndrome. No swallowing rehabilitation.

• Optic Nerve Sheath: For tumors threatening vision, CyberKnife can treat the lesion while keeping the optic nerve dose below the tolerance threshold—preserving or improving vision in many cases.

• Foramen Magnum: Tumors at the skull base exit where the brainstem meets the spinal cord. CyberKnife treats them without the mortality and morbidity associated with open surgery in this region.

What this means for you: A meningioma in a "surgical no-go zone" is not a death sentence—or a sentence to watch and wait. We can treat it with curative intent, preserving the nerves and vessels that make life worth living.

Capability 3: When It Comes Back — Salvage Without Re-Operation

"My meningioma was removed years ago, but it has returned. I cannot face another craniotomy. Is there a way to treat the recurrence without going back under the knife?"

The challenge: Meningiomas can recur years or even decades after complete surgical removal—particularly atypical (Grade II) or malignant (Grade III) variants, or when the initial resection was subtotal due to location. Re-operation carries higher risks due to scar tissue, making dissection more difficult and nerve injury more likely. Many patients are told "we cannot operate again safely."

Our answer: CyberKnife M6 as the first-line salvage for recurrent meningioma:

• Post-Surgical Recurrence: For tumors recurring at the prior resection bed or along the dural tail, CyberKnife delivers a focused ablative dose to the recurrence site—without dissecting through scarred tissue. Particularly effective for Grade II/III recurrences where surgery would be morbid.

• Post-Radiation Recurrence: For patients who previously received conventional radiation and now face recurrence, CyberKnife's sub-millimeter precision allows re-irradiation of the focal recurrence while keeping the cumulative dose to surrounding critical structures (brainstem, optic nerves, pituitary) within safe limits.

• For Progression After Incomplete Resection: When initial surgery could only remove 80–90% due to adherence to critical structures, CyberKnife treats the residual tumor definitively—completing the treatment without returning to the operating room.

• For Multiple Recurrences: Some patients face 2nd, 3rd, or even 4th recurrences over decades. CyberKnife can be used repeatedly for new focal recurrences—each time non-invasively—allowing a lifetime of management without cumulative surgical morbidity.

What this means for you: Recurrence does not mean another craniotomy. Whether your meningioma has returned once or multiple times, CyberKnife offers a non-invasive, repeatable salvage option that keeps you out of the operating room and preserves your quality of life.

3. Continuous Care & Frontier Access

Clinical Trial Fast-Track

When standard therapies reach their limit—particularly for Grade II/III meningiomas—we provide rapid access to China's full portfolio of Phase III clinical trials. For meningioma specifically, this includes trials of novel targeted agents (PDGFR, VEGFR, EGFR inhibitors), hormone therapy (mifepristone for progesterone-receptor positive tumors), and next-generation radiosurgery dose-escalation protocols—typically 3–5 years ahead of availability elsewhere. NGS-based molecular matching identifies trials targeting your specific tumor biology. Every enrollment is ethics-approved with full medical supervision.

Integrative Oncology & TCM

Our TCM program runs alongside your primary treatment as a "neurological vitality and symptom optimizer":

Toxicity Reduction: Herbal formulations help manage peritumoral edema and associated headache, reduce radiation-induced fatigue, support cognitive clarity, and mitigate post-surgical or post-SRS recovery symptoms.

Efficacy Enhancement: Selected preparations may improve tolerance to multi-modal therapy and support immune function.

Acupuncture provides additional support for headache, dizziness, neck stiffness, and treatment-related anxiety. The goal: preserve your neurological function, reduce symptom burden, and maintain your quality of life through years or decades of management.

4. Multidisciplinary Decision-Making

Every meningioma case is reviewed by a panel comprising neurosurgery (open and endoscopic), radiation oncology (CyberKnife SRS), neuroradiology, pathology, neurology (for seizure and symptom management), neuro-ophthalmology (for optic nerve involvement), and integrative medicine specialists. Meningioma decisions are uniquely complex: observation versus treatment; surgery versus SRS; timing of intervention; management of Grade II/III variants; and long-term surveillance planning.

The MDT convenes within 48 hours of complete documentation. Your plan is a consensus decision optimized for your tumor location, size, grade, symptoms, age, comorbidities, and your personal priorities.

5. Patient Case

Diagnosis:
Cavernous Sinus Tumor Consistent with Meningioma or Cavernous Hemangioma

Treatment Plan:

Phase I:
The patient initially received four fractions of CyberKnife radiosurgery, followed by observation and serial imaging surveillance. After substantial tumor shrinkage was achieved, a second phase of treatment was planned.

Following treatment, the patient experienced mild headache, which resolved completely after administration of mannitol and dexamethasone.

At the two-year follow-up, MRI demonstrated approximately 80% reduction in tumor volume.

Phase II:
A second course of low-dose CyberKnife radiosurgery was subsequently delivered to the residual lesion in order to minimize radiation-induced brain injury while protecting the optic nerve and adjacent critical structures.

Outcome:
The second-stage treatment was well tolerated without discomfort or complications.

At six years following initial CyberKnife treatment, MRI demonstrated approximately 95% tumor volume reduction.

At thirteen years of follow-up, MRI revealed near-complete disappearance of the lesion, with only minimal residual enhancement consistent with post-treatment scar tissue.

The patient remains clinically stable with no evidence of tumor progression.

6. About Fosun

Fosun Oncology Center

Led by Dr. Yang Jun, Prof. Luo Pengfei, and Prof. Chen Tao, the Fosun Oncology Center brings together more than 20 world-class medical experts, each with over a decade of extensive oncology experience. Supported by a comprehensive range of advanced therapies — including robotic surgery, precision radiotherapy, minimally invasive intervention, CAR-T cell therapy, and Tumor Treating Fields (TTFields) — the center delivers one-stop, integrated cancer care designed to make treatment more accessible, efficient, and high-quality for every patient.

Key Highlights

- Over 60,000 annual oncology patient admissions across Fosun’s major international hospitals in 2025

More than 17,000 cumulative TACE procedures completed between 2023 and 2025 at Fosun Hospital Guangzhou alone, with international patients accounting for over 10% of total cases

- More than 1,000 successful CyberKnife treatments performed, demonstrating world-class expertise in precision radiotherapy

- A 29.3% five-year survival rate achieved for Glioblastoma Multiforme (GBM) through combined TTFields therapy, representing a significant improvement over the 4.7% baseline

Core Services

- Robotic surgery

- Precision radiotherapy

- Minimally invasive intervention

- CAR-T cell therapy

- Tumor Treating Fields (TTFields)

- Medical oncology

- PET/CT imaging

- Pulmonary nodule diagnosis

- VIP inpatient wards

- Integrated oncology clinics

- Traditional Chinese medicine for oncology

- Cancer screening and early detection

- Genetic testing and counseling

Fosun & Fosun Health

Founded in 1992, Fosun has grown over the past three decades into a global innovation-driven consumer group. In 2007, Fosun International Limited was listed on the Main Board of the Hong Kong Stock Exchange (stock code: 00656.HK). As one of the few Chinese enterprises with strong global operational and investment capabilities, Fosun has developed substantial technological expertise and innovation capacity across multiple industries.

Established in 2010, Shanghai Fosun Health Technology is dedicated to building a world-renowned healthcare group in Asia. Today, the group operates 19 affiliated medical institutions across Foshan, Guangzhou, Shenzhen, Zhuhai, Shanghai, and other major cities, with a total of 6,600 hospital beds and 9 Internet Hospital licenses. Fosun Health ranks No. 1 among China’s private comprehensive medical groups. Its flagship institution, Fosun Foshan Chancheng Hospital, has ranked first among private hospitals in China for eight consecutive years and was honored with the 2026 Global Health Asia-Pacific “Oncological Medical Service Provider of the Year” award.

Fosun Foshan Chancheng Hospital

As the flagship hospital of Fosun Health, Fosun Foshan Chancheng Hospital was founded in 1958. The hospital currently hosts 28 key specialty development programs, including 2 provincial-level, 13 municipal-level, and 13 district-level key specialties. Its services span 22 medical disciplines, including spinal orthopedics, traditional Chinese medicine gynecology, obstetrics and gynecology, cardiovascular medicine, clinical laboratory medicine, anesthesiology, pediatrics, critical care medicine, ultrasound medicine, rehabilitation medicine, general practice, general surgery, and urology.

The hospital is equipped with globally advanced medical technologies, including the CyberKnife system and the Da Vinci Surgical Robot. It has 1,750 approved hospital beds and a multidisciplinary team of more than 2,800 medical professionals. The hospital records nearly 3.19 million outpatient visits annually and more than 67,000 inpatient discharges each year.

Fosun Foshan Chancheng Hospital has received numerous prestigious recognitions, including:

Global Health Asia-Pacific “Traditional Chinese Medicine Hospital of the Year”

Global Health China “Hospital of the Year”

No. 1 ranking on the GAHA Top 500 Private Hospitals in China list for eight consecutive years

The hospital has also been recognized as:

A National Model Unit for Improved Medical Services

A National Drug Clinical Trial Institution (GCP)

A National Standardized Residency Training Base

Guangzhou Fosun Chancheng Hospital (Guangzhou Xinshi Hospital)

Established in 2003, Guangzhou Fosun Chancheng Hospital specializes in cardiovascular medicine, oncology, and neurosciences. The hospital has established a National Chest Pain Center, Stroke Center, Trauma Center, and MDT Center, supporting the development of emergency medicine, obstetrics and gynecology, intensive care, anesthesiology, gastroenterology, general surgery, urology, and general practice.

The hospital operates more than 800 inpatient beds and 48 clinical and medical technology departments, supported by a team of over 880 healthcare professionals.

Guangzhou Fosun Chancheng Hospital has received several honors and industry recognitions, including:

EMBA Innovation Practice Base

Guangdong Private Medical Reform & Innovation Brand

Guangdong Private Medical Industry Pioneer Brand

Outstanding Brand Hospital for Medical Investment Contribution

Upload your contrast-enhanced brain MRI, CT bone window imaging, prior surgical records and pathology (if applicable), and current symptom description. The Fosun Health Meningioma MDT Panel will conduct a comprehensive evaluation and deliver a personalized preliminary treatment plan—including CyberKnife SRS candidacy, surgical versus non-surgical strategy, and long-term surveillance protocol—within 48 hours.